Search

BackgroundEdaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19). One of the Study 19 inclusion criteria was forced vital capacity (FVC) ≥80% of predicted (≥80%p). Therefore, the study provided no information on edaravone efficacy in subjects with FVC ObjectiveTo address the question of the efficacy of edaravone in ALS patients with FVC MethodsPost-hoc analysis of Study 19 comparing edaravone efficacy at week 48 in subjects with FVC24 ≥80%p vs ResultsWith edaravone treatment, subjects in both the FVC24 ≥80%p and the FVC24 ConclusionALS subjects in the Study 19 placebo arm had a slowing in disease progression, even when edaravone was added with an FVC of